Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

PATHFINDER: Avapritinib Induces Rapid Responses in Advanced Systemic Mastocytosis

Three-quarters of patients with advanced systemic mastocytosis (SM) responded to treatment with the oral KIT D816V inhibitor avapritinib, according to interim results from the...
On location

Evaluating a New Bispecific CAR T-Cell Therapy for B-Cell Lymphomas

In a first-in-human phase I clinical trial of a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, four of five treated patients with lymphoma...
On location

Copanlisib Plus Rituximab Improves Progression-Free Survival in Indolent Non-Hodgkin Lymphoma

Combining copanlisib with rituximab reduced the risk of progression or death by 48%, compared with placebo plus rituximab, in patients with relapsed advanced indolent...
On location

Investigating Tyrosine Kinase Inhibitors for ITP

In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators shared updates on two kinase inhibitors for the treatment...
On location

ADAMTS13 Activity Levels Predict iTTP Recurrence

A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress confirms the value of longitudinal quarterly assessment of ADAMTS13...
On location

Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A

In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress, gene therapies for hemophilia A demonstrated durable increases...
On location

Is It Time for a Paradigm Shift for CAPS Treatment?

Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic antiphospholipid syndrome (CAPS), according to research presented at the...
On location

Late-Breaking Abstracts Address Thrombosis and COVID-19

A growing body of clinical evidence indicates that COVID-19 infection predisposes patients to arterial and venous thrombosis and thrombotic complications. At the International Society...
On location

Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A

The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be safe and effective in young boys with previously untreated...
On location

FLT180a: A New Gene Therapy Candidate for Severe Hemophilia B

In a small study of patients with severe hemophilia B, the novel adeno-associated virus (AAV) gene therapy FLT180a was associated with increased factor IX...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title